2026-04-11T08:14:21Z
https://pub.unibl.org/oai
oai:pub.unibl.org:40912
2024-06-12T14:24:19Z
FRIO162 Comparable Safety and Immunogenecity and Sustained Efficacy after Transition To SB2 (An Infliximab Biosimilar) vs Ongoing Infliximab Reference Product In Patients with Rheumatoid Arthritis: Results of Phase III Transition Stud
/unibl/author/JS Smolen
/unibl/author/JY Choe
/unibl/author/Nenad Prodanović
/unibl/author/I Staykov
/unibl/author/E Dokoupilova
/unibl/author/A Baranauskaite
/unibl/author/R Yatsyshyn
/unibl/author/M Mekić
/unibl/author/W Porawska
/unibl/author/H Ciferska
/unibl/author/K Jedrichovicz-Rosiak
/unibl/author/A Zelinska
/unibl/author/Z Lee
/unibl/author/YH Rho
2016
Academic Article
text
10
10
/unibl/sci/idNaucniRad:25131
ANNALS OF THE RHEUMATIC DISEASES
0003-4967
ANNALS OF THE RHEUMATIC DISEASES
0003-4967
J. Smolen, J. Choe, N. Prodanović, I. Staykov, E. Dokoupilova, A. Baranauskaite, R. Yatsyshyn, M. Mekić, W. Porawska, H. Ciferska, K. Jedrichovicz-Rosiak, A. Zelinska, Z. Lee, Y. Rho, FRIO162 Comparable Safety and Immunogenecity and Sustained Efficacy after Transition To SB2 (An Infliximab Biosimilar) vs Ongoing Infliximab Reference Product In Patients with Rheumatoid Arthritis: Results of Phase III Transition Stud, ANNALS OF THE RHEUMATIC DISEASES, pp. 10 - 10, 2016